Vitrectomy may improve the anti-VEGF response in some patients with ERM who do not respond to anti-VEGF therapy for PCV
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Traction forces in cases of epiretinal membrane (ERM) may antagonize the effects of anti-vascular endothelial growth factors (anti-VEGF) treatments and cause pharmacological resistance in patients with neovascular age-related macular degeneration.
📊
Key Findings & Data:Presently described is a case with polypoidal choroidal vasculopathy (PCV) in conjunction with ERM who demonstrated a partial response to intravitreal aflibercept injections.
💡
Conclusion & Impact:Vitrectomy may improve the anti-VEGF response in some patients with ERM who do not respond to anti-VEGF therapy for PCV
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Traction forces in cases of epiretinal membrane (ERM) may antagonize the effects of anti-vascular endothelial growth factors (anti-VEGF) treatments and cause pharmacological resistance in patients with neovascular age-related macular degeneration. Presently described is a case with polypoidal choroidal vasculopathy (PCV) in conjunction with ERM who demonstrated a partial response to intravitreal aflibercept injections. A pars plana vitrectomy with ERM peeling was performed. After surgery, optical coherence tomography showed an improvement in the macular morphology and complete resolution of subretinal fluid. His visual acuity remained stable. Vitrectomy may improve the anti-VEGF response in some patients with ERM who do not respond to anti-VEGF therapy for PCV
🔖
Cite This Article
KIRMACI, A., DEMİRCAN, A., YASA, D., ALKIN, Z. (2018). Effect of Epiretinal Membrane Peeling on Intravitreal Aflibercept Therapy Response for Polypoidal Choroidal Vasculopathy: A Case Report. BEYOGLU EYE JOURNAL, Cilt: 3 - Sayı: 1, 29–33. https://ajindex.com/articles/146236
Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, et al. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. BMC Ophthalmol 2016;16:127
Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2015;253:1471–7
Alkin Z, Ozkaya A, Ayranci Osmanbasoglu O, Agca A, Karakucuk Y, Yazici AT, et al. The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab. ScientificWorldJournal 2013;2013:958724
Karaca EE, Kepez Yldz B, Çubuk MÖ, Özdek Ş. Epiretinal Mebranes in Neovasculer Age-Related Macular Degeneration: Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy. Retina 2015;35:1540–6
Pierro L, Zampedri E, Milani P, Gagliardi M, Isola V, Pece A. Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration. Clin Ophthalmol 2012;6:219–23
Schulze S, Hoerle S, Mennel S, Kroll P. Vitreomacular traction and exudative age-related macular degeneration. Acta Ophthalmol 2008;86:470–81
Roller AB, Mahajan VB, Boldt HC, Abramoff MD, Russell SR, Folk JC. Effects of vitrectomy on age-related macular degeneration. Ophthalmology 2010;117:1381–6
Kimura S, Morizane Y, Toshima S, Hosogi M, Kumase F, Hosokawa M, et al. Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. Graefes Arch Clin Exp Ophthalmol 2016;254:1731–6.